GlassScriptPhysician profile
Alan I Wu
NPI 1013116128
$3,047.24
in general payments reported to CMS, 2019-2025
15 companies · $1,351 in 2025
The $1,351 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $169 · 2021: $210 · 2022: $24.12 · 2023: $58.94 · 2024: $792 · 2025: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,201.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $856.02 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $494.93 | 2020-2025 | Ozempic |
| Gilead Sciences, INC. | $372.26 | 2019-2025 | Yeztugo |
| Astrazeneca Pharmaceuticals LP | $366.37 | 2024-2025 | Airsupra, Breztri |
| Genentech USA, INC. | $354.29 | 2019-2021 | |
| Biomerieux INC | $146.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.12 | 2019-2020 | |
| Abbvie INC. | $74.46 | 2024-2025 | |
| Pfizer INC. | $64.27 | 2023-2025 | |
| Amarin Pharma, INC. | $60.00 | 2020 | |
| Exact Sciences Corporation | $52.09 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $47.98 | 2019 | |
| Amgen INC. | $46.93 | 2025 | Evenity, Prolia |
| Teva Pharmaceuticals USA, INC. | $19.39 | 2019 | |
| Team_makena_llc | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.